Medical News

RSS

Researchers find way to get beneficial effects of estrogen without increasing woman's risk of cancer

Researchers at UT Southwestern Medical Center have pinpointed a set of biological mechanisms through which estrogen confers its beneficial effects on the cardiovascular system, independent of the hormone's actions on cancer. Their investigation suggests that drugs targeting a specific subpopulation of estrogen receptors found outside the cell nucleus might activate the cardiovascular benefits of estrogen without increasing cancer risk.

24 Jun 2010

Mixed progress on MDGs, additional advancement still possible, report says

Poverty rates in 10 African countries have been halved over the last two decades, while child mortality rates have gone up in six sub-Saharan African countries, according to a report (.pdf) from the Overseas Development Institute (ODI) and the U.N. Millennium Campaign, which emphasized that progress towards the Millennium Development Goals (MDGs) is possible, the Associated Press/St. Petersburg Times reports (Straziuso, 6/22).

24 Jun 2010

Pfizer announces suspension of osteoarthritis clinical program for tanezumab

Pfizer Inc. announced today the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration. The worldwide suspension – which is effective immediately – follows a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement.

24 Jun 2010

Health Diagnostic Laboratory announces new capability to run CYP2C19 genetic test

Health Diagnostic Laboratory, Inc., a leader in disease state management, today announced its new capability to run the CYP2C19 genetic test. HDL, Inc., headquartered in the Virginia Biotechnology Research Park, has added CYP2C19 to its comprehensive panel of tests to help physicians better personalize treatment based on an expanded, total patient profile.

24 Jun 2010

Miller-McCune examines debate over redistribution of some foreign aid funds from HIV/AIDS to other diseases

Through the lens of health conditions faced by people in Mbarara, Uganda, Miller-McCune examines the debate over redistributing some foreign aid funds from HIV/AIDS to fight other diseases.

24 Jun 2010

Health Canada issues Screening Acceptance Letter in connection with NexMed's NDS for Vitaros

NexMed, Inc., a specialty CRO with a pipeline of product candidates based on the NexACT technology, today announced that Health Canada has confirmed acceptance of the Company's CMC response for review. The Screening Acceptance Letter from Health Canada was issued in connection with its New Drug Submission for Vitaros, the Company's topical treatment for erectile dysfunction.

24 Jun 2010

FDA schedules Advisory Committee meeting to review Orexigen's Contrave NDA

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Division of Metabolic and Endocrine Drug Products Advisory Committee meeting on December 7, 2010 to review the Company's New Drug Application (NDA) for Contrave® (naltrexone sustained release (SR)/bupropion SR) for the treatment of obesity.

24 Jun 2010

Treatment options for patients with MS

The best one-word description for multiple sclerosis is "unpredictable," according to the June issue of Mayo Clinic Women's HealthSource. MS interferes with the communication between the brain and the rest of the body. Just how that interference plays out in symptoms is different for everyone -- thus, the unpredictable label.

24 Jun 2010

Former solicitor general: Roe v. Wade likely to be overturned

Politico reports that Walter Dellinger, a former acting solicitor general and liberal scholar, "predicted Tuesday night that the Supreme Court will overturn Roe vs. Wade, the landmark decision that gives women abortion rights." Conservatives on the court have made overturning the decision a "trophy," he said, more likely to be won if a Republican chooses a replacement for Justice Anthony Kennedy.

24 Jun 2010

Progen receives Nasdaq delisting notification

Progen Pharmaceuticals Limited today received notice from the Nasdaq Stock Market that its securities will be delisted due to a minimum bid price deficiency under Nasdaq Listing Rule 5500(a)(2).

24 Jun 2010

Globalpost examines efforts to stop violence against women worldwide

"Thirty years after the first treaty on women's rights was adopted by the United Nations, millions of cases involving beatings, marital rapes, honor killings and genital mutilation lead to deaths, medical injuries, failed pregnancies, abortions and psychological damage," according to a GlobalPost article that reports on the rising number of individuals, communities and governments worldwide committing to end violence against women.

24 Jun 2010

Biosense Webster's CARTOXPRESS Module, LASSO NAV Circular Mapping Catheter receive FDA clearance

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today that the U.S. Food and Drug Administration (FDA) has cleared for marketing the CARTOXPRESS™ Software Module and the LASSO® NAV Circular Mapping Catheter for use with the CARTO® XP Mapping System.

24 Jun 2010

Kensey Nash, St. Jude Medical sign two-year Supply Agreement

Kensey Nash Corporation, a regenerative medicine company, today announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. The agreement provides for Kensey Nash to be the exclusive outside supplier of collagen plugs, one of the key resorbable components of the Angio-Seal Vascular Closure Device, the leading arterial puncture closure product in the world.

24 Jun 2010

HHS launching health website for consumers next week

Kaiser Health News staff writer Phil Galewitz, working in collaboration with USA Today, writes about the soon-to-be launched federal health care site.

24 Jun 2010

Positive results from Phase II PK study for Topical Interferon Alpha-2b announced

Helix BioPharma Corp. today announced positive Phase II pharmacokinetic findings for Topical Interferon Alpha-2b in patients with low-grade cervical lesions.

24 Jun 2010

BioSante closes $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced closing of a previously announced sale of an aggregate of $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante received net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

24 Jun 2010

White House unveils consumer protections in health law

New health-law-prompted regulations were released Tuesday, Kaiser Health News reports. The regulations could likely affect a small fraction of the country, but address key insurance concerns.

24 Jun 2010

New hospital gown ensures patient privacy, dignity

Patients seeking to conserve privacy and personal dignity - i.e. anyone who's ever been forced to wear a traditional hospital gown that often reveal too much - may soon bid adieu peek-a-book hospital garb. Indeed, researchers from the University of Montreal have designed a revolutionary healthcare garment that preserves modesty.

24 Jun 2010

Entelos agree to the terms of non-exclusive perpetual license to Metabolism Physiolab platform for Pfizer

Entelos, Inc. announced today that it has agreed to the terms of a non-exclusive perpetual license to its Metabolism Physiolab platform for Pfizer Inc. The perpetual license will include access for Pfizer to Entelos' PhysioLab Modeler software and its PhysioLab Simulation Server.

24 Jun 2010

Free seminar to help parents understand signs and characteristics of ADHD

Learning Lab, Brentwood will present a free seminar, Does My Child Have ADHD? Diagnosing and What's Next?, on Thursday June 24, 2010 from 7:00-8:00 PM at the Maryland Farms YMCA in Brentwood. The seminar will be presented by Dr. David Elkins, Clinical Psychologist and Supervising Psychologist of Learning Lab, and Vanessa Adams, School Psychologist of Learning Lab, Brentwood.

24 Jun 2010